<DOC>
	<DOCNO>NCT01261793</DOCNO>
	<brief_summary>The primary objective study confirm clinical efficacy epratuzumab treatment subject Systemic Lupus Erythematosus ( SLE ) .</brief_summary>
	<brief_title>Study Epratuzumab Versus Placebo Subjects With Moderate Severe General Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Positive antinuclear antibody ( ANA ) Screening ( Visit 1 ) Current clinical diagnosis Systemic Lupus Erythematosus ( SLE ) American College Rheumatology ( ACR ) criteria least 4 11 criterion meet Active moderate severe SLE activity demonstrate British Isles Lupus Assessment Group Index ( BILAG ) Active moderate severe SLE disease demonstrate SLE disease activity index ( SLEDAI ) total score On stable SLE treatment regimen , include mandatory corticosteroid immunosuppressant antimalarial Subjects breastfeed , pregnant , plan become pregnant Subjects active , severe SLE disease activity involve renal system Subjects active , severe , neuropsychiatric SLE , define neuropsychiatric element score BILAG level A disease . Subjects evidence immunosuppressive state Subjects , opinion investigator , particularly high risk significant infection History malignant cancer , except follow treated cancer : cervical carcinoma situ , basal cell carcinoma , dermatological squamous cell carcinoma . Subjects receive live vaccination within 8 week prior screen ( Visit 1 ) . Subjects history infection , include limited concurrent acute chronic viral hepatitis B C Subjects substance abuse dependence relevant concurrent medical condition Subjects history thromboembolic event within 1 year screen Visit . Subjects significant hematologic abnormality Subject receive treatment anti B cell antibody within 12 month prior screen ( visit 1 ) Subject use oral anticoagulant ( include ) nonsteroidal antiinflammatory drug ( NSAIDs ) within 12 week prior screen ( Visit 1 ) Subject previously participate study previously receive epratuzumab treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Lupus</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>B-Cell immunotherapy</keyword>
	<keyword>Epratuzumab</keyword>
</DOC>